NEW YORK — In this video commentary from HemOnc Today New York, Stephen J. Schuster, MD, discusses treatment with CD19-directed chimeric antigen receptor T cells for non-Hodgkin lymphoma.
CAR T cells provide “an incremental step” toward more treatment options for patients who have failed conventional induction chemotherapy and salvage chemotherapy, or who progress after hematopoietic stem cell transplantation, Schuster said.
The toxicities associated with CAR T-cell therapy are unique but manageable, said Schuster, director of lymphoma program and Robert and Margarita Louis-Dreyfus professor in chronic lymphocytic leukemia and lymphoma clinical care and research at University of Pennsylvania.
During his presentation, Schuster discussed data for three CD-19-directed CAR T-cell therapies — tisagenlecleucel (Kymriah, Novartis), axicabtagene ciloleucel (Yescarta, Kite Pharma) and lisocabtagene maraleucel (Juno).
“All three of these products and this treatment approach offers patients — for whom we don’t have existing therapies that are adequate — the potential in at least a third of cases to have a prolonged disease-free remission after a single course of therapy,” Schuster said.
Shuster reports research support from/consultant roles with Celgene, Gilead, Merck and Novartis.